Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Inclusion Criteria:

- patients with mild to moderate hypertension, untreated or currently taking
antihypertensive therapy

- treated patients (using antihypertensive drugs within 4 weeks prior to first visit)
must have an office msSBP ≥ 145 mmHg and < 180 mmHg after washout epoch and after 4
weeks run-in epoch

- untreated patients (either newly diagnosed or those patients with a history of
hypertension but have not been taking any antihypertensive drugs for at least 4 weeks
prior to first visit) must have an offcie msSBP ≥ 150 mmHg and < 180 mmHg at
screening and 1 week after screening and must have an office msSBP ≥ 145 mmHg and <
180 mmHg after 4 weeks run-in epoch

- patients must successfully complete ABPM and pass technical requirements to be
qualified for randomization

Exclusion Criteria:

- Malignant or severe hypertension (grade 3 of WHO classification; msDBP ≥110 mmHg
and/or msSBP ≥ 180 mmHg)

- History of angioedema, drug-related or otherwise

- History or evidence of a secondary form of hypertension, including but not limited to
any of the following: renal parenchymal hypertension, renovascular hypertension
(unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary
hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease
(PKD), drug-induced hypertension

- Patients who previously entered a LCZ696 study and had been randomized or enrolled to
receive active drug treatment